Table 2 Comparison of CTCs, primary tumor, and metastatic tissue by HER2 status in patients with MBC
Total | CTC-HER2-negative | CTC-HER2-positive | |
|---|---|---|---|
n (%) | n (%) | ||
PRIM-HER2 status (total) | 107 | 70 (65 %) | 37 (35 %) |
Negative | 91 | 64 (70 %) | 27 (30 %) |
Positive | 16 | 6 (38 %) | 10 (62 %) |
MET-HER2 status (total) | 46 | 36 (78 %) | 10 (22 %) |
Negative | 40 | 32 (80 %) | 8 (20 %) |
Positive | 6 | 4 (67 %) | 2 (33 %) |